###begin article-title 0
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 83 91 <span type="species:ncbi:9606">patients</span>
Association of HLA Class I and Class II genes with bcr-abl transcripts in leukemia patients with t(9;22) (q34;q11)
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 54 62 54 62 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 284 292 284 292 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 81 89 <span type="species:ncbi:9606">patients</span>
Based on the site of breakpoint in t(9;22) (q34;q11), bcr-abl fusion in leukemia patients is associated with different types of transcript proteins. In this study we have seen the association of HLA genes with different types of bcr-abl transcripts. The association could predict the bcr-abl peptide presentation by particular HLA molecules.
###end p 2
###begin title 3
Methods
###end title 3
###begin p 4
###xml 196 204 196 204 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 313 321 313 321 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 34 42 <span type="species:ncbi:9606">patients</span>
The study included a total of 189 patients of mixed ethnicity with chronic myelogenous leukemia and acute lymphocytic leukemia who were being considered for bone marrow transplantation. Typing of bcr-abl transcripts was done by reverse transcriptase PCR method. HLA typing was performed by molecular methods. The bcr-abl and HLA association was studied by calculating the relative risks and chi-square test.
###end p 4
###begin title 5
Results
###end title 5
###begin p 6
###xml 35 37 35 37 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
Significant negative associations (p < 0.05) were observed with HLA-A*02 (b2a2, e1a2), -A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303 (b2a2, b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -DRB1*0701 (b3a2), and -DRB1*1101 (b2a2).
###end p 6
###begin title 7
Conclusions
###end title 7
###begin p 8
###xml 42 50 42 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 314 322 314 322 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 415 423 415 423 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
The negative associations of a particular bcr-abl transcript with specific HLA alleles suggests that these alleles play a critical role in presenting peptides derived from the chimeric proteins and eliciting a successful T-cell cytotoxic response. Knowledge of differential associations between HLA phenotypes and bcr-abl fusion transcript types would help in developing better strategies for immunization with the bcr-abl peptides against t(9;22) (q34;q11)-positive leukemia.
###end p 8
###begin title 9
Background
###end title 9
###begin p 10
###xml 211 217 211 217 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-abl </italic>
###xml 275 279 275 279 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 302 303 302 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B1">1</xref>
###xml 304 305 304 305 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B6">6</xref>
###xml 318 324 318 324 <italic xmlns:xlink="http://www.w3.org/1999/xlink">c-abl </italic>
###xml 387 391 387 391 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 475 478 475 478 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr</italic>
###xml 520 523 520 523 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr</italic>
###xml 568 571 567 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr</italic>
###xml 574 575 573 574 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B7">7</xref>
###xml 605 609 604 608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 663 666 662 665 <italic xmlns:xlink="http://www.w3.org/1999/xlink">abl</italic>
###xml 882 883 881 882 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B8">8</xref>
###xml 884 885 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B9">9</xref>
###xml 905 909 904 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 937 940 936 939 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr</italic>
###xml 960 963 959 962 <italic xmlns:xlink="http://www.w3.org/1999/xlink">abl</italic>
###xml 1053 1055 1052 1054 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1080 1084 1078 1082 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 1131 1135 1129 1133 <italic xmlns:xlink="http://www.w3.org/1999/xlink">abl </italic>
###xml 1213 1215 1211 1213 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B11">11</xref>
###xml 1263 1271 1261 1269 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 1388 1390 1386 1388 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B12">12</xref>
###xml 1391 1393 1389 1391 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B14">14</xref>
###xml 1638 1640 1636 1638 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 1641 1643 1639 1641 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 1779 1781 1777 1779 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B16">16</xref>
###xml 51 59 <span type="species:ncbi:9606">patients</span>
###xml 114 122 <span type="species:ncbi:9606">patients</span>
The t(9;22) (q34;q11) translocation seen in 90% of patients with chronic myelogenous leukemia (CML) and about 10% patients with acute lymphocytic leukemia (ALL) results in juxtaposition of the 3' segment of the c-abl proto-oncogene on chromosome 9 with the 5' segment on the bcr gene on chromosome 22 [1-6]. Breaks in c-abl gene generally involve exon 2, also known as a2. Breaks in the bcr occur in one of the three following regions: the major breakpoint cluster region (M-bcr), the minor breakpoint cluster region (m-bcr) or the micro breakpoint cluster region (mu-bcr) [7]. Breakpoints occurring in m-bcr involve introns 13 and 14 and join exon 13 or 14 with abl, resulting in the fusion transcripts e13a2 (also known as b2a2) and e14a2 (also known as b3a2), respectively. These transcripts lead to production of a 8.5-kb transcript coding for a 210-kD chimeric protein (p210) [8,9]. Breakpoints in m-bcr involve the first intron of bcr, exon 1 joins with abl, resulting in a smaller fusion transcript, e1a2, that codes for a 190-kD protein (p190) [10]. Breakpoints in the mu-bcr involve intron 19, the joining of exon 19 with abl results in a fusion transcript e19a2, that codes for a 230-kD protein (p230) [11]. Although tyrosine kinase is activated in all bcr-abl fusion transcripts, the p190 form has been shown to have more transforming potential than p210 in vitro and in vivo [12-14]. Fusion transcripts b3a2 and b2a2, which are translated into p210, account for the majority of CML cases, while the fusion transcript e1a2, which is translated into p190, is seen primarily in t(9;22)-positive ALL and the blastic phase of CML [10,15]. The rare fusion transcript e19a2, resulting in p230, is associated primarily with the entity known as chronic neutrophilic leukemia [16].
###end p 10
###begin p 11
###xml 227 235 227 235 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 891 899 891 899 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 80 85 <span type="species:ncbi:9606">human</span>
Several reports indicate an association between t(9;22) (q34;q11) and different human leukocyte antigen (HLA) alleles. This association suggests a possible role for T-cell cytotoxicity in the pathogenesis of diseases linked to bcr-abl fusion proteins resulting from t(9;22) (q34;q11). Different HLA alleles have different predilections for the sequence of peptides they can present to T cells. In order to elicit a T-cell response, a peptide must bind to the HLA molecule prior to its presentation to the T cell. Since a given HLA allele can bind and present only peptides with certain sequence constraints, the ability of an individual to elicit a successful T-cell cytotoxic response to cells carrying foreign or newly mutated proteins depends on the set of HLA alleles that individual has inherited. Thus, individuals carrying certain HLA alleles capable of binding peptides derived from bcr-abl fusion transcripts can in principle be considered to have a biological advantage in fighting the disease over individuals lacking these particular HLA alleles.
###end p 11
###begin p 12
###xml 104 112 104 112 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 254 262 254 262 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 71 79 <span type="species:ncbi:9606">patients</span>
In studying the association between the distribution of HLA alleles in patients with different types of bcr-abl transcripts, a positive association suggests that a particular HLA allele does not effectively bind and present peptides derived from a given bcr-abl transcript. Likewise, a negative association suggests that the binding and presentation of a peptide is effective and elicits a successful T-cell cytotoxic response with destruction of leukemia cells.
###end p 12
###begin p 13
###xml 85 93 85 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 217 225 217 225 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
The aim of this study was to analyze the disease association between HLA alleles and bcr-abl fusion transcripts in greater detail than has so far been studied. First, we assessed the HLA association with a particular bcr-abl transcript, i.e., b2a2 or b3a2 or e1a2, and not with CML in general. Second, unlike earlier studies that were limited to low-resolution allele typing, this study used high-resolution typing for HLA class II genes.
###end p 13
###begin title 14
Methods
###end title 14
###begin p 15
###xml 15 23 <span type="species:ncbi:9606">patients</span>
###xml 154 162 <span type="species:ncbi:9606">patients</span>
###xml 942 950 <span type="species:ncbi:9606">patients</span>
A total of 189 patients comprising of 163 with CML and 26 with ALL, all with t(9;22) (q34;q11) and known HLA types, were included in this study. Of these patients, 28 expressed b2a2 and b3a2 transcripts, while 68 expressed the b2a2 transcript, 76 the b3a2 transcript, and 17 the e1a2 transcript. The comparisons were made with healthy, potential bone marrow donors that were HLA typed at our laboratory. 376 donors were typed for HLA class I and 267 donors for HLA class II. The donor population is a multiracial group of both related and unrelated prospective bone-marrow donors with no significant clinical history. The gene frequencies are not at odds with reported gene frequencies in general populations for prevailing races. We decided to use our internal gene frequencies from this donor population for three reason: First, it is a multiracial group in which no racial bias was made, more representative of the population the reported patients came from than any specific racial group typically used to determine HLA gene frequencies. Second, it is a group for which high-resolution high-quality typing is readily available making it possible to evaluate allelic gene frequency differences, rather than differences at the serologic low-resolution level. Third, it is a group for which not only the HLA phenotype is available, but also the genotype, that is, the haplotypes were determined in each case, particularly in regard to class II genes.
###end p 15
###begin title 16
###xml 10 18 10 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
Typing of bcr-abl fusion transcripts by reverse-transcriptase PCR
###end title 16
###begin p 17
###xml 235 264 235 264 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Invitrogen Lifetechnologies, </italic>
###xml 562 589 561 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Invitrogen Lifetechnologies</italic>
Leukocytes prepared by erythrocyte lysis of bone marrow aspirate (1-2 ml) and peripheral blood (10 ml) samples collected in ethylene diamine tetraacetic acid were used for RNA isolation. Total RNA was isolated by using Trizol reagent (Invitrogen Lifetechnologies, USA) according to the manufacturer's instruction. The integrity of RNA was determined by gel electrophoresis prior to reverse transcription (RT). Total RNA (1-5 mug) from samples with intact 28 s and 18 s RNA was converted to cDNA by using random hexamers and Superscript II reverse transcriptase (Invitrogen Lifetechnologies) according to the recommendations of the manufacturer.
###end p 17
###begin p 18
###xml 43 51 43 51 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 82 86 82 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">abl </italic>
###xml 113 117 113 117 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr </italic>
###xml 146 148 146 148 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B17">17</xref>
###xml 295 297 295 297 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B18">18</xref>
###xml 298 300 298 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B19">19</xref>
Each sample was amplified in duplicate for bcr-abl in a multiplex RT-PCR using an abl primer in combination with bcr b2- and e1-specific primers [17]. The t(9;22)-positive cell lines KBM7, K562, and B15, which carry b2a2, b3a2, and e1a2 fusion genes, respectively, served as positive controls. [18,19] The HL60 cell line was used as negative control.
###end p 18
###begin title 19
HLA typing
###end title 19
###begin p 20
###xml 225 232 225 232 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Biotest</italic>
###xml 641 651 641 651 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Genovision</italic>
###xml 660 669 660 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">Pel-freez</italic>
HLA typing was performed by molecular methods. For class I, HLA typing was done at the intermediate-resolution level by using enzyme linked probe hybridization assay with sequence-specific oligonucleotide probe (ELPHA-SSOP) (Biotest, Germany). The sequence-specific oligonucleotide probes were used to identify polymorphic sequence motifs. The hybridization between probe and target DNA from the series of amplified PCR products was detected by a method adapted from the protein enzyme linked immunosorbent assay (ELISA) technique. For class II, HLA typing was done at the high-resolution level by using the sequence specific primers (SSP) (Genovision, USA or Pel-freez, USA). The technique uses a battery of known sequence specific primers to amplify specific alleles or group of alleles. This typing method is based on the fact that a completely matched primer will be used more efficiently in the PCR reaction than a partially mismatched primer. The electrophoresis bands generated were compared with the kit standards.
###end p 20
###begin title 21
Statistical analysis
###end title 21
###begin p 22
###xml 229 237 229 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 181 189 <span type="species:ncbi:9606">Patients</span>
HLA gene frequencies (not phenotype frequency) were calculated in two different populations: (1) Healthy individuals typed as potential candidates for donating bone marrow; and (2) Patients diagnosed as having CML or ALL in whom bcr-abl transcripts were identified.
###end p 22
###begin p 23
###xml 83 84 83 84 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T1">1</xref>
###xml 412 415 412 415 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr</italic>
###xml 416 420 416 420 <italic xmlns:xlink="http://www.w3.org/1999/xlink">abl </italic>
###xml 1131 1133 1124 1126 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 388 396 <span type="species:ncbi:9606">patients</span>
###xml 536 544 <span type="species:ncbi:9606">patients</span>
###xml 582 590 <span type="species:ncbi:9606">patients</span>
###xml 700 708 <span type="species:ncbi:9606">patients</span>
###xml 810 818 <span type="species:ncbi:9606">patients</span>
###xml 1213 1220 <span type="species:ncbi:9606">patient</span>
###xml 1298 1305 <span type="species:ncbi:9606">patient</span>
The sizes of the gene pools of these populations for HLA typing are shown in Table 1. In order to obtain more accurate gene frequencies, the largest population of typed donors was used. This resulted in a larger population for class I genes (376 individuals) than for class II genes (268 individuals). The frequencies of the HLA-A, -B, -DRB1 and -DQB1 alleles for the three groups of CML patients with different bcr-abl transcripts were compared with their gene frequencies in the healthy donor group. The frequencies of HLA alleles in patients were evaluated in 192 chromosomes of patients with b2a2 transcirpts (96 individuals, 68 with only b2a2 and 28 with both b2a2 and b3a2); 208 chromosomes of patients with b3a2 (104 individuals, 76 with only b3a2 and 28 with both b2a2 and b3a2); and 34 chromosomes of patients with e1a2 (17 individuals). The comparisons were made by calculating the relative risks. Chi-squares were also calculated to assess the statistical significance of the differences. With (nu) = (r-1)(c-1) = 1 degree of freedom and a significance level of alpha = 0.05 needed to reject the null hypothesis, the chi2 statistic must be > 3.84. Since ours is an international referral center with a patient population of diverse racial backgrounds, it was not possible to compare the patient data with the standard HLA frequencies based on ethnicity. We therefore used the healthy bone marrow donor population for comparison.
###end p 23
###begin p 24
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B20">20</xref>
###xml 138 140 138 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B22">22</xref>
###xml 224 226 224 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B10">10</xref>
###xml 227 229 227 229 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B15">15</xref>
###xml 251 253 251 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B23">23</xref>
###xml 279 281 279 281 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B24">24</xref>
The binding scores were calculated on the basis of the amino acid sequence of the peptide and the HLA molecule as described elsewhere [20-22]. The sequences of e1a2, b3a2, and b2a2 junctional peptides are EGAFHGDAEALQRPVAS [10,15], ATGFKQSSKALQRPVAS [23], and IPLTINKEEALQRPVAS [24].
###end p 24
###begin title 25
Results and discussion
###end title 25
###begin p 26
###xml 38 39 38 39 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 40 41 40 41 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
###xml 42 43 42 43 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
###xml 111 113 109 111 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 162 164 160 162 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 885 886 883 884 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T2">2</xref>
###xml 251 258 <span type="species:ncbi:9606">patient</span>
Our findings are summarized in Tables 2,3,4, which include only statistically significant observations with chi2 > 3.84, corresponding to a significance level of p < 0.05. Relative risk > 1 indicates that a particular HLA allele is more frequent in a patient population with a particular transcript than within the corresponding healthy population. Relative risk < 1 indicates a negative association, with a gene frequency significantly smaller than in the corresponding general population. Significant negative associations with b2a2 were seen with HLA-A*02, -A*68, -B*14, -B*15, -B*40, -DQB1*0303, -DQB1*0603, and -DRB1*1101. Significant positive association was seen with HLA-A*01, -A*23, -A*66, -B*37, -B*38, -B*42, -B*45, -B*49, -B*53, -B*56, -B*62, -DQB1*0201, -DQB1*0402, -DQB1*0609, -DRB1*0301, -DRB1*0302, -DRB1*0901, -DRB1*1001, -DRB1*1201, -DRB1*1202, and -DRB1*1503 (Table 2).
###end p 26
###begin p 27
###xml 299 300 299 300 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T3">3</xref>
Significant negative associations with b3a2 were seen with HLA-A*68, -B*14, -B*15, -DQB1*0303, and DRB1*0701. Significant positive association were seen with HLA-A*25, -B*37, -B*49, -B*51, -B*53, -B*56, -B*60, -B*62, -DQB1*0609, -DRB1*0405, -DRB1*0802, -DRB1*0901, -DRB1*1001, and -DRB1*1503 (Table 3).
###end p 27
###begin p 28
###xml 268 269 268 269 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T4">4</xref>
Significant negative associations with e1a2 were seen with HLA-A*02, -A*68, -B*14, and -DRB1*0401. Significant positive association were seen with HLA-A*01, -A*11, -A*26, -B*08, -B*49, -B*53, -B*62, -DQB1*0201, -DQB1*0502, -DRB1*0301, -DRB1*0802, and DRB1*1601 (Table 4).
###end p 28
###begin p 29
The relative maximum binding scores of various peptides with the HLA types are also shown in the corresponding tables. The scores are particularly high for HLA-A*02, -A*68, -B*14, and -B*53 (all with b2a2), HLA-A*68, -B*14, and -B*62 (all with b3a2) and HLA-A*01, -A*02, -B*08, and -B*14 (all with e1a2).
###end p 29
###begin p 30
###xml 257 259 255 257 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2 </sup>
###xml 309 311 307 309 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 23 31 <span type="species:ncbi:9606">patients</span>
Interestingly, 1.6% of patients with t(9;22) (q34;q11) lacked HLA-DRB3, -DRB4, and -DRB5 alleles. This contrasts with the healthy group of which only 0.13% lacked these alleles. The 2 x 2 contingency table analysis yielded a likelihood ratio of 25 and a chi2 of 42.8, indicating a statistical significance of p < 0.001.
###end p 30
###begin p 31
###xml 16 24 16 24 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 733 735 733 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B25">25</xref>
###xml 736 738 736 738 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B27">27</xref>
###xml 745 753 745 753 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 916 917 916 917 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 1029 1037 1029 1037 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
The presence of bcr-abl transcripts in patients with leukemia appears to be associated with both HLA class I and II alleles. In general, exogenous antigens are processed to peptides in the endocytic compartment and are presented by HLA class II to CD4+ T cells. On the other hand, endogenous peptides resulting from cleavage of proteins are transferred by the transport-associated proteins to the endocytoplasmic reticulum. In the endocytoplasmic reticulum, these peptides bind to newly synthesized HLA class I molecules, and the resulting complexes are transported to the cell surface to be recognized by CD8+ T cells. It has been shown however, that endogenous antigens can be processed by both class I and class II HLA molecules [25-27]. The bcr-abl transcripts in leukemia cells would be endogenous peptides and would normally be presented by HLA class I molecules. In our study and other studies cited in Table 5, negative associations with both HLA class I and II alleles have been seen. A possible explanation is that the bcr-abl transcripts are presented by both HLA class I and class II.
###end p 31
###begin p 32
###xml 74 82 74 82 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 139 140 139 140 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 218 226 218 226 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 376 384 376 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 520 526 520 526 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 615 617 615 617 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B28">28</xref>
###xml 1113 1115 1113 1115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B29">29</xref>
###xml 1490 1492 1490 1492 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B30">30</xref>
###xml 1600 1608 1600 1608 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 1683 1685 1683 1685 <italic xmlns:xlink="http://www.w3.org/1999/xlink">p </italic>
###xml 1987 1993 1987 1993 <italic xmlns:xlink="http://www.w3.org/1999/xlink">et al </italic>
###xml 2282 2283 2282 2283 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T5">5</xref>
###xml 2286 2288 2286 2288 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B36">36</xref>
###xml 811 818 <span type="species:ncbi:9606">patient</span>
###xml 930 938 <span type="species:ncbi:9606">patients</span>
###xml 1236 1244 <span type="species:ncbi:9606">patients</span>
###xml 2349 2357 <span type="species:ncbi:9606">patients</span>
There are published reports of both negative and positive associations of bcr-abl transcripts with HLA class I and class II alleles (Table 5). By a positive association it is meant that individuals having a particular bcr-abl transcript are more likely to be endowed with a particular HLA phenotype. By a negative association it is meant that individuals showing a particular bcr-abl transcript are less likely to have a given HLA phenotype. Most of these studies were done with low-resolution HLA typing data. Posthuma et al claimed that HLA-A3 and -B8 are associated with a diminished risk of development of CML [28]. On the basis of a large multi-center data from the European bone marrow transplant program (n = 1462), they also claimed that HLA-DR4 is associated with diminished risk of CML. They compared patient data with data from unaffected individuals from the registry of bone marrow donors worldwide (n = 500596). The patients and controls were matched by country. The odds ratio for HLA-DR3 was 0.86 (95% confidence interval CI 0.75-0.98) and for -DR4 combined with -B8, was 0.84 (95% CI 0.72-0.98) [29]. A limitation of this study was that no high-resolution class II typing was done. It was also assumed that all the CML patients expressed the p210 protein, which is present in a majority but not all cases of CML. Pawelec and Wagner have questioned their claim on the basis of its reliance on low-resolution typing and have stressed the need for high-resolution HLA typing [30]. Our present study not only used high-resolution HLA class II typing but also included all three types of bcr-abl transcripts (b2a2, b3a2, and e1a2). Significant negative associations with p < 0.05 was seen with HLA-A*02 (b2a2, e1a2), -A*68 (b2a2, b3a2, e1a2), -B*14 (b2a2, b3a2, e1a2), -B*15 (b2a2, b3a2), -B*40 (b2a2), -DQB1*0303 (b2a2, b3a2), -DQB1*0603 (b2a2), -DRB1*0401 (e1a2), -DRB1*0701 (b3a2), and -DRB1*1101 (b2a2). In a similar study using high-resolution HLA-DRB1 typing, Yasukawa et al reported positive association with HLA-DRB1*1201 (b2a2), and -DRB1*0403, -DRB1*0802, -DRB1*1403, DRB1*1405 (all with b3a2), and a negative association with -DRB1*0405, -DRB1*08032, -DRB1*1502 (all with b2a2) and -DRB1*08032, and -DRB1*1501 (both with b3a2) in a Japanese population (Table 5) [36]. However, the study included only 50 cases and included no patients with the e1a2 transcript. Furthermore, association with HLA-DQB1 typing was not assessed. Our study had a larger population (n = 189) though of mixed ethnicity. The common findings of the two studies include positive association with HLA-DRB1*1201 (b2a2) and -DRB1*0802 (b3a2). There were no common HLA alleles with a negative association.
###end p 32
###begin p 33
###xml 5 6 5 6 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="table" rid="T6">6</xref>
###xml 65 73 <span type="species:ncbi:9606">patients</span>
Tabe 6 shows HLA class II haplotypes with increased frequency in patients with the various types of bcr-abl transcripts.
###end p 33
###begin p 34
###xml 644 652 644 652 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 4 12 <span type="species:ncbi:9606">patients</span>
###xml 526 533 <span type="species:ncbi:9606">patient</span>
The patients in our study had HLA class II typing that included HLA-DRB1*, -DRB3*, -DRB4*, -DRB5*, -DQB1* and -DPB1*. We included in our results the statistical data on HLA-DRB1* and -DQB1*. Our study is unique among published reports by incorporating HLA-DQB1 data. Unlike HLA-DRB1 and -DQB1, HLA-DRB3, -DRB4, and -DRB5 are not expressed by all individuals; expression depends on the haplotype. An interesting observation was the fact that the frequencies of absence of HLA-DRB3, -DRB4 and -DRB5 phenotype were higher in the patient pool then in the healthy donors. This could imply that HLA-DRB3, -DRB4, and -DRB5 alleles are associated with bcr-abl transcript presentation.
###end p 34
###begin p 35
###xml 4 12 4 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 56 58 56 58 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B31">31</xref>
###xml 59 61 59 61 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B34">34</xref>
###xml 257 259 257 259 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B35">35</xref>
###xml 260 262 260 262 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B39">39</xref>
###xml 356 364 356 364 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 407 409 407 409 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B40">40</xref>
###xml 410 412 410 412 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="B41">41</xref>
The bcr-abl transcripts can generate a T-cell response [31-34]. Successful allogeneic, autologous, and HLA-identical sibling dendritic cell immunization strategies against CML with b3a2-p210 peptide have also been tried, with generation of T-cell response [35-39]. There are reports of successful in vitro generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes in ALL [40,41]. The restriction was confirmed by loss of the cytotoxic effect in the presence of anti-HLA-DR and preservation of the effect when anti-HLA class I was used.
###end p 35
###begin title 36
Conclusions
###end title 36
###begin p 37
###xml 14 22 14 22 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 311 319 311 319 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 466 473 466 473 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl</italic>
###xml 573 581 573 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
###xml 712 720 712 720 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
It seems that bcr-abl peptides are presented by many different HLA types. The negative association could occur because the early leukemogenic events are contained by a T-cell cytotoxic response and this prevents disease proliferation. A positive association could mean that the HLA molecules do not present the bcr-abl transcripts. We hold the theoretical assumption that HLA-restricted T-cell cytotoxicity performs an immunosurveillance role in the pathogenesis of bcr-abl-transcript leukemias. Should this assumption hold, knowledge of the HLA association with different bcr-abl transcripts would have diagnostic and prognostic implications. It would also help in improving strategies of immunization with the bcr-abl peptides against t(9;22) (q34;q11) leukemia.
###end p 37
###begin title 38
Competing interests
###end title 38
###begin p 39
None declared.
###end p 39
###begin title 40
Authors' contributions
###end title 40
###begin p 41
###xml 80 88 80 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
SM carried out the data collection and analysis and writing the manuscript. The bcr-abl typing was done in the lab of RL. HLA typing was done in the lab supervised by PC. RL and PC did the study design and analysis of the data. All authors read and approved the final manuscript.
###end p 41
###begin title 42
Pre-publication history
###end title 42
###begin p 43
The pre-publication history for this paper can be accessed here:
###end p 43
###begin p 44

###end p 44
###begin title 45
Acknowledgements
###end title 45
###begin p 46
We wish to acknowledge the editorial assistance by Ms. Kathryn Hale, Department of Scientific Publications, M. D. Anderson Cancer Center.
###end p 46
###begin article-title 47
###xml 23 28 <span type="species:ncbi:9606">human</span>
A minute chromosome in human chronic granulocytic leukemia
###end article-title 47
###begin article-title 48
Ph1-positive acute leukaemia and chronic granulocytic leukaemia: one or two diseases?
###end article-title 48
###begin article-title 49
A new consistent chromosomal abnormality in chronic myelogenous leukemia identified by quinacrine fluorescence and Giemsa staining
###end article-title 49
###begin article-title 50
A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukemia
###end article-title 50
###begin article-title 51
Philadelphia chromosomal breakpoints are clustered within a limited region, bcr, on chromosome 22
###end article-title 51
###begin article-title 52
Chronic myelogenous leukemia: A concise update
###end article-title 52
###begin article-title 53
The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype
###end article-title 53
###begin article-title 54
Fused transcript of abl and bcr genes in chronic myelogenous leukemia
###end article-title 54
###begin article-title 55
The chronic myelogenous leukemia-specific p210 protein is the product of the bcr-abl hybrid gene
###end article-title 55
###begin article-title 56
Unique fusion of bcr and c-abl genes in Philadelphia chromosome-positive acute lymphoblastic leukemia
###end article-title 56
###begin article-title 57
New type of BCR/ABL junction in Philadelphia chromosome-positive chronic myelogenous leukemia
###end article-title 57
###begin article-title 58
Alternative forms of the bcr-abl oncogene have quantitatively different potencies for stimulation of immature lymphoid cells
###end article-title 58
###begin article-title 59
Tyrosine kinase activity and transformation potency of bcr-abl oncogene products
###end article-title 59
###begin article-title 60
###xml 26 41 <span type="species:ncbi:10090">transgenic mice</span>
Acute leukemia in BCR/ABL transgenic mice
###end article-title 60
###begin article-title 61
A new fused transcript in Philadelphia chromosome-positive acute lymphocytic leukaemia
###end article-title 61
###begin article-title 62
Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR/ABL with C3/A2 junction)
###end article-title 62
###begin article-title 63
###xml 112 120 <span type="species:ncbi:9606">patients</span>
Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation
###end article-title 63
###begin article-title 64
###xml 0 5 <span type="species:ncbi:9606">Human</span>
Human chronic myelogenous lekemia cell-line with positive Philadelphia chromosome
###end article-title 64
###begin article-title 65
###xml 9 14 <span type="species:ncbi:9606">human</span>
KBM-7, a human myeloid leukemia cell line with double Philadelphia chromosomes lacking normal c-ABL and BCR transcripts
###end article-title 65
###begin article-title 66
A geometric study of the amino acid sequence of class I HLA molecules
###end article-title 66
###begin article-title 67
A geometric and algebraic view of MHC-peptide complexes and their binding properties
###end article-title 67
###begin article-title 68
The propositional calculus of peptide binding to the major histocompatibility complex
###end article-title 68
###begin article-title 69
HLA-DR1-restricted bcr-abl (b3a2)-specific CD4+ T lymphocytes respond to dendritic cells pulsed with b3a2 peptide and antigen presenting cells exposed to b3a2-containing cell lysates
###end article-title 69
###begin article-title 70
The chronic myelocytic cell line K562 contains a breakpoint in bcr and produces a chimeric bcr/c-abl transcript
###end article-title 70
###begin article-title 71
Class II MHC molecules can use the endogenous pathway of antigen presentation
###end article-title 71
###begin article-title 72
MHC class II restriction presentation of intracellular antigen
###end article-title 72
###begin article-title 73
Processing pathways for presentation of cytosolic antigen to MHC class II-restricted T cells
###end article-title 73
###begin article-title 74
HLA-B8 and HLA-A3 coexpressed with HLA-B8 are associated with a reduced risk of the development of chronic myeloid leukemia
###end article-title 74
###begin article-title 75
HLA-DR4 is associated with a diminished risk of the development of chronic myeloid leukemia (CML)
###end article-title 75
###begin article-title 76
Is HLA-DR4 or the HLA-DRB1*0402 allele association with decreased risk for CML?
###end article-title 76
###begin article-title 77
###xml 51 56 <span type="species:ncbi:9606">human</span>
Recognition of BCR-ABL positive leukemic blasts by human CD4+ T cells elicited by primary in vitro immunization with a BCR-ABL breakpoint peptide
###end article-title 77
###begin article-title 78
###xml 87 92 <span type="species:ncbi:9606">human</span>
Recognition of peptides corresponding to the joining region of p210 bcr-abl protein by human T cells
###end article-title 78
###begin article-title 79
HLA class II-restricted antigen presentation of endogenous bcr-abl fusion protein by chronic myelogenous leukemia-derived dendritic cells to CD4+ T lymphocytes
###end article-title 79
###begin article-title 80
CD4+ cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner
###end article-title 80
###begin article-title 81
###xml 189 197 <span type="species:ncbi:9606">patients</span>
Generation of bcr-abl-specific cytotoxic T-lymphocytes by using dendritic cells pulsed with bcr-abl (b3a2) peptide: its applicability for donor leukocyte transfusions in marrow-grafted CML patients
###end article-title 81
###begin article-title 82
Bcr/abl+ autologous dendritic cells for vaccination in chronic myeloid leukemia
###end article-title 82
###begin article-title 83
Binding of BCR/ABL junctional peptides to major histocompatibility complex (MHC) class I molecules: studies in antigen processing defective cell lines
###end article-title 83
###begin article-title 84
###xml 15 23 <span type="species:ncbi:9606">patients</span>
Vaccination of patients with chronic myelogenous leukemia with bcr-abl oncogene breakpoint fusion peptides generates specific immune responses
###end article-title 84
###begin article-title 85
###xml 46 54 <span type="species:ncbi:9606">patients</span>
Tumor-specific CD4+ T lymphocytes from cancer patients are required for optimal induction of cytotoxic T cells against the autologous tumor
###end article-title 85
###begin article-title 86
Generation of HLA-DRB1*1501-restricted p190 minor bcr-abl (e1a2)-specific CD4+ T lymphocytes
###end article-title 86
###begin article-title 87
Generation of FAS-independent CD4 + cytotoxic T cell clone specific for p190 minor bcr-abl fusion peptide
###end article-title 87
###begin article-title 88
###xml 41 49 <span type="species:ncbi:9606">patients</span>
Analysis of HLA-DRB1 alleles in Japanese patients with chronic myelogenous leukemia
###end article-title 88
###begin article-title 89
###xml 71 79 <span type="species:ncbi:9606">patients</span>
Cytotoxic T-cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia
###end article-title 89
###begin article-title 90
###xml 9 14 <span type="species:ncbi:9606">human</span>
Specific human cellular immunity to bcr-abl oncogene-derived peptides
###end article-title 90
###begin article-title 91
###xml 86 91 <span type="species:ncbi:9606">human</span>
Two bcr-abl junctional peptides bind HLA-A3 molecules and allow specific induction of human cytotoxic T lymphocytes
###end article-title 91
###begin article-title 92
A BCR-ABL oncoprotein p210 b2a2 fusion region sequence is recognized by HLA-DR2a-restricted cytotoxic T lymphocytes and presented by HLA-DR-matched cells transfected with an L-Ii (b2a2) construct
###end article-title 92
###begin article-title 93
b3a2 BCR-ABL fusion peptides as targets for cytotoxic T cells in chronic myeloid leukemia
###end article-title 93
###begin article-title 94
Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein
###end article-title 94
###begin title 95
Figures and Tables
###end title 95
###begin p 96
*Numbers of HLA genes available in the different populations to calculate HLA allele frequencies (not the number of individuals in these populations taking into account that an individual carries two genes for each loci).
###end p 96
###begin p 97
###xml 53 61 <span type="species:ncbi:9606">patients</span>
b2a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
###end p 97
###begin p 98
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 3.84
###end p 98
###begin p 99
###xml 53 61 <span type="species:ncbi:9606">patients</span>
b3a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
###end p 99
###begin p 100
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 3.84
###end p 100
###begin p 101
###xml 53 61 <span type="species:ncbi:9606">patients</span>
e1a2 association with HLA Class I and II in leukemia patients and healthy donors with statistical analysis
###end p 101
###begin p 102
*Figures shown are the gene frequencies. For a significance level of = 0.05 needed to reject the null hypothesis, the chi square statistic must be > 3.84.
###end p 102
###begin p 103
###xml 39 47 39 47 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
Published data on HLA association with bcr-abl transcripts
###end p 103
###begin p 104
###xml 51 59 51 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink">bcr-abl </italic>
HLA class II haplotypes positively associated with bcr-abl transcripts. (Each line represents a haplotype. An "X" indicates positive association with the respective transcript.)
###end p 104

